Samsung Biologics selects Rapid Micro platform to automate critical microbiology quality control

 Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that Samsung Biologics (KRX: 207940.KS) has selected the Growth Direct® platform to automate its microbial quality control processes to deliver increased efficiency, more robust data integrity and scalable quality control operations.

https://www.globenewswire.com/news-release/2024/01/04/2803838/33206/en/Samsung-Biologics-selects-Rapid-Micro-Biosystems-Growth-Direct-platform-to-automate-critical-microbiology-quality-control-testing.html